Telazol (tiletamine-zolazepam)

Telazol is a fixed-ratio combination of tiletamine hydrochloride, a dissociative anesthetic, and zolazepam hydrochloride, a benzodiazepine tranquilizer, formulated in equal parts to provide reliable chemical immobilization and anesthesia in veterinary species. This unique combination capitalizes on the complementary pharmacological profiles of its components, with tiletamine providing dissociative anesthesia and analgesia while zolazepam contributes muscle relaxation, anxiolysis, and mitigation of the undesirable excitatory effects associated with dissociative anesthetics alone. In farm animal medicine, Telazol has become an invaluable tool for field immobilization, anesthesia induction, and procedures requiring rapid onset of effect without intravenous access.

The pharmacological mechanism of Telazol reflects the combined actions of its two components acting through distinct receptor systems. Tiletamine, structurally related to ketamine, produces its dissociative effects primarily through non-competitive antagonism of N-methyl-D-aspartate (NMDA) receptors in the central nervous system, resulting in a cataleptic state characterized by profound analgesia, amnesia, and disconnection from environmental stimuli while maintaining certain protective reflexes. Zolazepam potentiates gamma-aminobutyric acid (GABA) receptor activity, producing central nervous system depression, muscle relaxation, and anxiolysis that complements tiletamine's effects.

Telazol is supplied as a lyophilized powder requiring reconstitution with sterile diluent before administration. When reconstituted with 5 mL of diluent, the resulting solution contains 100 mg/mL total drug concentration (50 mg/mL each of tiletamine and zolazepam). This concentrated formulation allows for small injection volumes, which is particularly advantageous for intramuscular administration in farm animals where large volumes may be impractical or painful. The reconstituted solution maintains stability for extended periods under proper storage conditions, making it practical for field use and emergency applications.

Regulatory considerations for Telazol use in food-producing animals are substantial and require careful attention. As a DEA Schedule III controlled substance, Telazol is subject to strict record-keeping, storage, and dispensing requirements. While FDA-approved for dogs and cats, its use in cattle, swine, sheep, goats, and other food animals constitutes extra-label drug use requiring a valid veterinarian-client-patient relationship, appropriate documentation, and establishment of withdrawal times. The FARAD database provides current withdrawal time recommendations, and veterinarians must ensure compliance with both controlled substance regulations and food safety requirements when using Telazol in livestock.

Chemical immobilization for examination, treatment, and transport represents one of the most valuable applications of Telazol in farm animal practice. The drug's effectiveness via intramuscular administration allows restraint of fractious or dangerous animals without requiring the intravenous access necessary for many other anesthetic agents. Cattle that cannot be safely handled for examination, treatment of injuries, or loading for transport may be immobilized with Telazol administered via pole syringe, dart, or hand injection when brief approach is possible. This capability is particularly valuable in range cattle management, wildlife-livestock interface situations, and emergency medical treatment of animals that cannot be safely restrained by conventional means.

Anesthesia induction in farm animals is a common indication for Telazol, particularly in situations where intravenous access is difficult or impossible to obtain in the conscious animal. The drug produces reliable sedation and immobilization following intramuscular injection, allowing subsequent placement of intravenous catheters and endotracheal tubes for maintenance anesthesia. This approach is particularly useful in fractious swine, unhandled cattle, and small ruminants where pre-anesthetic restraint poses safety concerns for personnel. The quality of induction is generally smooth, with adequate muscle relaxation for intubation in most cases.

Surgical procedures of moderate duration may be performed under Telazol anesthesia alone or with supplementation. Cesarean sections in cattle and swine represent important applications where the drug's reliable effect, reasonable duration, and field practicality are advantageous. Other surgical applications include wound repair, abscess drainage, fracture stabilization, dehorning in older cattle, and various reproductive surgeries. The analgesic properties of tiletamine provide some surgical analgesia, though supplementation with local or regional anesthesia and additional systemic analgesics is generally recommended for invasive procedures.

Diagnostic procedures requiring immobilization benefit from Telazol's combination of sedation, muscle relaxation, and analgesia. Radiographic examination of uncooperative patients, reproductive examination and semen collection in fractious breeding stock, and sampling procedures such as bone marrow aspiration or liver biopsy may be facilitated by Telazol administration. The preservation of certain reflexes, including swallowing and laryngeal function at moderate doses, provides some protection against aspiration, though monitoring remains essential.

Emergency and field applications capitalize on Telazol's stability, concentrated formulation, and reliable intramuscular absorption. Emergency treatment of injuries, extrication of trapped animals, and management of aggressive animals in mixed-species housing situations all represent scenarios where Telazol's characteristics provide significant practical advantages. The drug has also found application in zoological and wildlife medicine for species related to domestic farm animals, providing a bridge of experience between domestic livestock practice and wildlife immobilization.

Cattle dosing for Telazol varies significantly based on the degree of restraint required and patient factors, with intramuscular doses typically ranging from 2 to 6 mg/kg for chemical immobilization and light anesthesia. Lower doses of 2 to 3 mg/kg generally provide adequate sedation for minor procedures and examination in calm animals, while doses of 4 to 6 mg/kg are necessary for surgical anesthesia or immobilization of fractious stock. When used for anesthesia induction prior to inhalant maintenance, doses of 2 to 4 mg/kg intramuscularly or 1 to 2 mg/kg intravenously are typically sufficient. Individual variation is substantial, and dose selection should consider temperament, body condition, and the planned procedure.

Swine dosing recommendations for Telazol range from 4 to 8 mg/kg intramuscularly for immobilization and anesthesia, with higher doses generally required in excited or fractious animals. Pigs are often considered particularly responsive to Telazol, and the drug has become a standard choice for swine chemical immobilization in both clinical and research settings. For anesthesia induction, doses of 4 to 6 mg/kg intramuscularly provide reliable sedation allowing intravenous catheter placement and intubation. Intravenous administration, when feasible, allows more precise dose titration with typical induction doses of 2 to 4 mg/kg.

Small ruminant dosing for sheep and goats typically falls in the range of 4 to 12 mg/kg intramuscularly, with considerable species and individual variation. Goats generally require higher doses than sheep for equivalent effect and may show more variable responses. The combination of Telazol with alpha-2 agonists or other sedatives allows significant dose reduction while improving muscle relaxation and extending anesthetic duration. Doses should be calculated carefully based on accurate body weights, as overdosing can result in prolonged recovery and respiratory complications.

Administration technique significantly influences Telazol's onset, reliability, and safety. Intramuscular injection should be performed into large muscle masses such as the semimembranosus, semitendinosus, or gluteal muscles in cattle and the cervical muscles or ham in swine. Deep injection ensures complete drug deposition in muscle tissue, as subcutaneous administration results in erratic absorption. Multiple injection sites may be required for larger volumes to avoid tissue irritation and improve absorption reliability. The onset of effect following intramuscular administration typically occurs within 5 to 10 minutes, though excited animals may require longer.

Combination protocols using Telazol with other agents extend its utility and improve anesthetic quality. The addition of xylazine or other alpha-2 agonists (creating "TKX" or similar combinations) provides enhanced muscle relaxation, analgesia, and sedation while reducing Telazol dose requirements. Butorphanol may be added for additional analgesia. These combinations are particularly useful for field anesthesia where inhalant maintenance is not available. Careful calculation of each component's dose is essential to avoid excessive central nervous system and cardiovascular depression.

Withdrawal time considerations for Telazol in food animals require consultation with FARAD for current recommendations, as no FDA-approved withdrawal periods exist for extra-label food animal use. Conservative estimates suggest meat withdrawal periods of at least 30 days for cattle and swine, reflecting tiletamine's extended elimination half-life in some species. Milk withdrawal recommendations are similarly extended, typically 4 to 7 days minimum. As a controlled substance, detailed records of Telazol administration including animal identification, dose, date, and withdrawal time assigned are mandatory and must be maintained for DEA compliance as well as food safety documentation.

Respiratory effects of Telazol include dose-dependent respiratory depression that may progress to apnea at higher doses or in sensitive individuals. Tiletamine maintains respiratory function better than many other anesthetic agents, but the combination with zolazepam increases respiratory depression potential. Oxygen supplementation should be available whenever Telazol is administered, and monitoring of respiratory rate and character is essential throughout the anesthetic period. Ruminant species present additional respiratory considerations due to the risk of regurgitation and aspiration, though the preservation of laryngeal reflexes at moderate doses provides some protection.

Cardiovascular effects of Telazol generally include mild increases in heart rate and blood pressure due to tiletamine's sympathomimetic properties, which may partially offset the cardiovascular depression associated with zolazepam. This cardiovascular stability represents an advantage over some alternative agents, particularly in hypovolemic or stressed animals. However, animals with pre-existing cardiovascular disease may be at increased risk for arrhythmias or excessive blood pressure elevation. Monitoring of heart rate and rhythm is recommended during Telazol anesthesia.

Recovery characteristics from Telazol vary considerably between species and individuals and represent an important consideration for drug selection. Cattle typically show prolonged recovery compared to some other species, with animals remaining recumbent for 60 to 120 minutes or longer following immobilizing doses. Recovery may be characterized by ataxia, disorientation, and difficulty rising, necessitating placement in safe environments free from hazards. Swine generally recover more quickly, though excitement during recovery can occur. Small ruminants show variable recovery patterns influenced by dose and individual sensitivity.

Excitatory phenomena during induction and recovery are potential side effects of Telazol, reflecting the dissociative nature of tiletamine. Muscle rigidity, opisthotonos, and spontaneous movement may occur, though zolazepam's muscle relaxant properties reduce these effects compared to tiletamine alone. Vocalization during recovery is common in some species and does not necessarily indicate distress. Excessive external stimulation during induction and recovery phases should be minimized to reduce the incidence of excitatory responses.

Other reported adverse effects include hypersalivation, particularly in ruminant species, which contributes to aspiration risk and should prompt positioning of animals to facilitate drainage. Emesis may occur in species capable of vomiting, though this is less relevant in ruminants. Corneal drying during prolonged procedures requires protection with ophthalmic lubricants. Injection site reactions are generally minimal but may include transient swelling or discomfort. Allergic reactions are rare but possible with any pharmaceutical agent.

Telazol is contraindicated in animals with known hypersensitivity to either tiletamine or zolazepam, or to any chemically related compounds. Prior adverse reactions to dissociative anesthetics such as ketamine may predict tiletamine sensitivity, and previous benzodiazepine reactions warrant caution with the zolazepam component. Animals with a history of seizures or central nervous system disorders require careful evaluation before Telazol use, as dissociative agents have been associated with both proconvulsant and anticonvulsant effects depending on circumstances.

Severe hepatic or renal dysfunction represents a relative contraindication to Telazol use in farm animals. Both tiletamine and zolazepam undergo hepatic metabolism with renal excretion of metabolites, and impaired organ function may result in prolonged drug effects and increased toxicity risk. Animals with known liver disease, urinary obstruction, or severe kidney disease should receive Telazol only when alternative agents are not suitable and with appropriate dose reduction and extended monitoring. Clinical assessment of hepatic and renal function may not be practical in field situations, necessitating careful patient evaluation.

Production stage restrictions limit Telazol use in certain food animal populations. The drug should be used with caution in pregnant animals, particularly in late gestation, as both components cross the placenta and may affect fetal cardiovascular and respiratory function. While Telazol has been used successfully for cesarean sections, neonatal monitoring and support must be available. Lactating animals intended for commercial milk production require extended withdrawal periods that may make Telazol impractical. Animals intended for imminent slaughter should not receive Telazol unless appropriate withdrawal times can be observed.

Controlled substance regulations create additional limitations on Telazol use. The drug may only be administered under the supervision of a licensed veterinarian with appropriate DEA registration for Schedule III substances. Storage must meet security requirements, and detailed records of acquisition, use, and disposal are mandatory. These regulatory requirements may limit Telazol availability in some practice situations and necessitate careful compliance documentation. Use in animals not under a valid veterinarian-client-patient relationship is prohibited, and the drug should not be dispensed for owner administration.

Alpha-2 adrenergic agonists represent the most common drugs combined with Telazol in farm animal practice, producing enhanced sedation, improved muscle relaxation, and extended anesthetic duration. Xylazine, detomidine, and medetomidine are all used in combination protocols with Telazol, with the resulting mixtures often designated by acronyms (TKX for Telazol-ketamine-xylazine combinations, though Telazol already contains the dissociative component). These combinations allow reduced doses of each component, potentially improving safety margins while achieving superior anesthetic quality. However, cardiovascular depression, particularly bradycardia, may be pronounced with alpha-2 agonist combinations.

Opioid analgesics are frequently combined with Telazol to improve analgesia for surgical procedures. Butorphanol is commonly used due to its favorable safety profile and reversibility, while morphine and hydromorphone provide stronger analgesia for major surgery. These combinations enhance central nervous system depression and may increase respiratory depression risk, requiring appropriate monitoring and dose adjustment. The analgesic synergism allows reduced Telazol doses while providing adequate surgical anesthesia for invasive procedures.

Other central nervous system depressants including phenothiazine tranquilizers, barbiturates, and propofol produce additive or synergistic effects when combined with Telazol. These interactions may be exploited therapeutically to reduce drug doses but increase the potential for excessive sedation, respiratory depression, and cardiovascular compromise. Particular caution is warranted when Telazol is administered to animals that have received other sedatives or when sequential anesthetic agents are used. The duration of interaction extends throughout the elimination period of all drugs involved.

Drug interactions affecting metabolism may alter Telazol pharmacokinetics, though specific interactions in food animals are not well-characterized. Agents that inhibit hepatic cytochrome P450 enzymes may prolong the effects of both tiletamine and zolazepam. Ionophore antibiotics commonly used in cattle and poultry production do not have documented direct interactions with Telazol but warrant consideration in comprehensive drug interaction assessment. Similarly, concurrent antimicrobial therapy and other medications commonly administered to farm animals should be reviewed for potential interactions, though clinically significant interactions are infrequently reported.

Controlled substance security and documentation requirements mandate careful attention when using Telazol in farm animal practice. As a DEA Schedule III substance, Telazol must be stored in a securely locked cabinet with access limited to authorized personnel. Records must be maintained documenting receipt, administration (including patient identification, dose, and date), and disposal of any unused drug. Inventory reconciliation should be performed regularly, and discrepancies must be reported appropriately. Veterinarians are responsible for ensuring compliance with all federal and state controlled substance regulations.

Food safety considerations are paramount when using Telazol in animals intended for human consumption. The extended withdrawal times necessary for this combination product may limit its practical application in some food animal situations. Clear communication with producers regarding withdrawal requirements is essential to prevent violative residues in meat or milk. Treated animals must be clearly and permanently identified to prevent inadvertent slaughter or milk sale before withdrawal periods are complete. Documentation requirements for extra-label drug use must be fulfilled, including the scientific basis for assigned withdrawal times.

Human safety during Telazol handling and administration requires attention to both the pharmacological effects of the drug and the hazards associated with handling immobilized livestock. Personnel should avoid self-injection, which could result in significant sedation and incapacitation. Appropriate protective equipment should be worn when handling reconstituted drug. Additionally, immobilized animals may recover suddenly and unpredictably, and personnel should maintain awareness of the potential for injury from recovering animals. Handling protocols should account for the delayed recovery characteristic of Telazol.

Environmental and disposal considerations apply to Telazol as they do to other pharmaceutical agents. Unused reconstituted drug should be disposed of according to applicable regulations for controlled substances, typically requiring witnessed destruction and documentation. Containers and associated materials should be disposed of appropriately to prevent environmental contamination and potential exposure of non-target species or humans. The controlled substance nature of Telazol requires that disposal records be maintained as part of the overall inventory documentation.

Monitoring requirements during Telazol anesthesia include continuous observation of respiratory function, cardiovascular status, body temperature, and depth of anesthesia. Oxygen supplementation should be available, and personnel should be prepared to provide respiratory support if needed. Eye protection with ophthalmic lubricant prevents corneal desiccation. Positioning of recumbent animals should facilitate drainage of saliva and prevent regurgitation aspiration. Recovery monitoring should continue until the animal has regained protective reflexes and the ability to maintain sternal recumbency safely.

Unreconstituted Telazol powder should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F). The lyophilized powder is stable under these conditions until the expiration date printed on the vial. Storage requirements include security measures appropriate for Schedule III controlled substances, typically a locked cabinet or safe with limited key access. Protection from light is recommended, and the product should be kept in its original container until reconstitution. Inventory should be maintained and reconciled according to DEA requirements.

Reconstituted Telazol solution demonstrates excellent stability when properly stored, maintaining potency for extended periods that make it practical for field use. When reconstituted with 5 mL of sterile diluent to produce a 100 mg/mL solution, the product is stable for 4 days at room temperature or 14 days under refrigeration (2°C to 8°C). Some practitioners prepare multiple vials in advance for anticipated needs, though inventory control and security requirements must be maintained. The solution should be inspected before each use for particulate matter or discoloration, and any abnormal vials should be discarded.

Disposal of Telazol must comply with DEA regulations for Schedule III controlled substances in addition to general pharmaceutical waste requirements. Unused or expired drug should be destroyed in a manner that renders it irretrievable, typically through witnessed destruction by authorized personnel or return to a reverse distributor authorized to handle controlled substances. Documentation of disposal must include the date, quantity destroyed, method of destruction, and signatures of witnesses. Empty vials should be defaced or destroyed to prevent diversion and disposed of according to local regulations. All disposal records become part of the required controlled substance documentation and must be maintained for the period specified by DEA regulations.

Cattle breed variations significantly influence Telazol dose requirements and response characteristics in both beef and dairy operations. Bos indicus breeds, including Brahman and Brahman-cross cattle, demonstrate increased sensitivity to the excitatory effects of dissociative anesthetics and may benefit from enhanced premedicaton or combination protocols to ensure smooth induction and recovery. Conversely, these breeds may show somewhat increased resistance to the sedative components, potentially requiring dose adjustment. European beef breeds and dairy cattle generally respond more predictably, though individual variation remains substantial across all breeds.

Swine breed considerations reflect the diversity of modern pig genetics and their varied responses to anesthetic agents. Commercial swine breeds selected for lean meat production may show increased stress sensitivity and potentially altered drug distribution due to differences in body composition. Heritage breeds and miniature pigs used in research settings may have different dose requirements that should be established based on clinical experience rather than simple extrapolation from commercial swine data. Young pigs, regardless of breed, typically require relatively higher doses per kilogram than mature animals.

Small ruminant species variations between sheep and goats create important dosing considerations for Telazol. Goats consistently require higher doses than sheep of comparable body weight for equivalent anesthetic effect, reflecting fundamental differences in drug metabolism and sensitivity between these species. Within species, breed variations are less well-characterized but may be significant. Hair sheep breeds may differ from wool breeds, and dairy goat breeds may respond differently than meat goat breeds. Individual assessment and conservative initial dosing with supplementation as needed represent prudent approaches.

Production type and physiological status influence Telazol requirements across all farm animal species. Dairy animals present withdrawal time considerations that may limit practical application during lactation. Beef cattle in good body condition may require different doses than thin or debilitated animals. Pregnant animals require careful dose calculation and consideration of potential fetal effects, while neonatal patients should generally not receive Telazol until more mature. Male animals, particularly intact males during breeding season, may be more excitable and require enhanced premedication or combination protocols for safe handling.

Ketamine represents the most closely related alternative to Telazol's dissociative component, offering similar mechanism of action through NMDA receptor antagonism. Ketamine requires combination with sedatives or muscle relaxants for optimal effect, essentially recreating Telazol's combination principle through separate agents. This approach allows flexibility in dosing each component independently but requires more complex calculations and multiple injections. Ketamine has established withdrawal times for food animals and is classified as a Schedule III controlled substance, similar to Telazol. The choice between ketamine combinations and Telazol often depends on availability, cost, and clinician preference.

Alpha-2 agonist combinations provide an alternative approach to chemical immobilization in farm animals that may be appropriate when dissociative anesthesia is not desired or contraindicated. Xylazine, detomidine, and medetomidine produce profound sedation with muscle relaxation and some analgesia, though the quality of immobilization and anesthesia differs from dissociative protocols. These agents are reversible with atipamezole or other alpha-2 antagonists, providing an advantage when rapid recovery is desired. Combination of alpha-2 agonists with opioids may approach the immobilization quality of Telazol for some applications.

Other injectable anesthetic options for farm animals include propofol for intravenous induction, barbiturates such as thiopental where still available, and alfaxalone. Each offers different characteristics regarding onset, duration, recovery quality, and cardiovascular effects that may make them preferable for specific situations. Propofol requires intravenous access, limiting field applicability compared to Telazol's intramuscular effectiveness. Inhalant anesthetics provide the gold standard for maintenance anesthesia but require specialized equipment not always available in farm animal field practice, making injectable protocols including Telazol-based combinations essential components of the food animal anesthesia armamentarium.